Zynex reaffirms Q2 EPS view 3c-7c, consensus 5c

Sees Q2 revenue $43.5M-$45.5M, consensus $44.6M. Zynex announced preliminary results for Q2. “Zynex continues to see strong growth in our pain management division across device and supply sales. Q2 orders increased 51% over the same period in 2022, providing further proof of our ability to deliver consistently strong profitable growth as we expand sales territories. We are excited by our progress in patient monitoring as that division continues to ramp up. We recently received FDA clearance on our CM-1600 fluid monitor, providing more comfortable and accurate monitoring to patients and hospitals.” said Thomas Sandgaard, CEO of Zynex. “We are confirming our previous estimates for Q2 revenue of $43.5M- $45.5M and earnings per share between 3c-7c,” said Sandgaard. “Our Q2 revenue estimate is an increase of approximately 21% over the prior year period, and I am pleased with our continued strong momentum, solid order growth, and continued productivity in our sales force.”